Antidepressant use during pregnancy and risk of congenital heart defects: A case-time-control study

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Antidepressant use during pregnancy and risk of congenital heart defects : A case-time-control study. / Sun, Yuelian; Pedersen, Lars Henning; Wu, Chun Sen; Petersen, Irene; Sørensen, Henrik Toft; Olsen, Jørn.

In: Pharmacoepidemiology and Drug Safety, Vol. 28, No. 9, 01.09.2019, p. 1180-1193.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Sun, Yuelian ; Pedersen, Lars Henning ; Wu, Chun Sen ; Petersen, Irene ; Sørensen, Henrik Toft ; Olsen, Jørn. / Antidepressant use during pregnancy and risk of congenital heart defects : A case-time-control study. In: Pharmacoepidemiology and Drug Safety. 2019 ; Vol. 28, No. 9. pp. 1180-1193.

Bibtex

@article{3f2db13183784e03b138895016f13133,
title = "Antidepressant use during pregnancy and risk of congenital heart defects: A case-time-control study",
abstract = "Abstract Purpose We estimated the association between maternal antidepressant (AD) use in early pregnancy and risk of congenital heart defects. Methods We applied a case-time-control design with the aim of controlling for confounding from time-invariant factors and compared the results of the design to results from a cohort design in a population of 792 685 singletons born alive in Denmark during 1995-2008. In the case-time-control design, we identified children diagnosed with a congenital heart defect in the first 5 years of life (cases) and compared maternal AD use in the risk period (the first 3 months of pregnancy) and the reference period (gestational months 5-7). A nondiseased control group was included to adjust for time trends of exposure. In the cohort design, we identified children whose mothers redeemed at least one AD prescription in the first 3 months of pregnancy (the exposed) and two other groups including the unexposed children with maternal AD prescriptions in the 12 months before pregnancy. We applied conditional logistic regression and logistic regression to compute odds ratios (ORs) and 95% confidence intervals (CIs). Results The case-time-control OR for any congenital heart defect was 1.03 (95% CI, 0.61-1.73), which was similar to the OR (1.09, 95% CI, 0.88-1.35) from the cohort design when we compared the exposed children with the unexposed children with maternal AD use before pregnancy. Conclusions The case-time-control design provided results similar to the cohort design when the cohort design had a better confounder control strategy. We discussed the strengths and drawbacks of case-time-control design.",
keywords = "antidepressants, case-time-control, cohort design congenital heart defects, pharmacoepidemiology, pregnancy",
author = "Yuelian Sun and Pedersen, {Lars Henning} and Wu, {Chun Sen} and Irene Petersen and S{\o}rensen, {Henrik Toft} and J{\o}rn Olsen",
year = "2019",
month = sep,
day = "1",
doi = "10.1002/pds.4844",
language = "English",
volume = "28",
pages = "1180--1193",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "JohnWiley & Sons Ltd.",
number = "9",

}

RIS

TY - JOUR

T1 - Antidepressant use during pregnancy and risk of congenital heart defects

T2 - A case-time-control study

AU - Sun, Yuelian

AU - Pedersen, Lars Henning

AU - Wu, Chun Sen

AU - Petersen, Irene

AU - Sørensen, Henrik Toft

AU - Olsen, Jørn

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Abstract Purpose We estimated the association between maternal antidepressant (AD) use in early pregnancy and risk of congenital heart defects. Methods We applied a case-time-control design with the aim of controlling for confounding from time-invariant factors and compared the results of the design to results from a cohort design in a population of 792 685 singletons born alive in Denmark during 1995-2008. In the case-time-control design, we identified children diagnosed with a congenital heart defect in the first 5 years of life (cases) and compared maternal AD use in the risk period (the first 3 months of pregnancy) and the reference period (gestational months 5-7). A nondiseased control group was included to adjust for time trends of exposure. In the cohort design, we identified children whose mothers redeemed at least one AD prescription in the first 3 months of pregnancy (the exposed) and two other groups including the unexposed children with maternal AD prescriptions in the 12 months before pregnancy. We applied conditional logistic regression and logistic regression to compute odds ratios (ORs) and 95% confidence intervals (CIs). Results The case-time-control OR for any congenital heart defect was 1.03 (95% CI, 0.61-1.73), which was similar to the OR (1.09, 95% CI, 0.88-1.35) from the cohort design when we compared the exposed children with the unexposed children with maternal AD use before pregnancy. Conclusions The case-time-control design provided results similar to the cohort design when the cohort design had a better confounder control strategy. We discussed the strengths and drawbacks of case-time-control design.

AB - Abstract Purpose We estimated the association between maternal antidepressant (AD) use in early pregnancy and risk of congenital heart defects. Methods We applied a case-time-control design with the aim of controlling for confounding from time-invariant factors and compared the results of the design to results from a cohort design in a population of 792 685 singletons born alive in Denmark during 1995-2008. In the case-time-control design, we identified children diagnosed with a congenital heart defect in the first 5 years of life (cases) and compared maternal AD use in the risk period (the first 3 months of pregnancy) and the reference period (gestational months 5-7). A nondiseased control group was included to adjust for time trends of exposure. In the cohort design, we identified children whose mothers redeemed at least one AD prescription in the first 3 months of pregnancy (the exposed) and two other groups including the unexposed children with maternal AD prescriptions in the 12 months before pregnancy. We applied conditional logistic regression and logistic regression to compute odds ratios (ORs) and 95% confidence intervals (CIs). Results The case-time-control OR for any congenital heart defect was 1.03 (95% CI, 0.61-1.73), which was similar to the OR (1.09, 95% CI, 0.88-1.35) from the cohort design when we compared the exposed children with the unexposed children with maternal AD use before pregnancy. Conclusions The case-time-control design provided results similar to the cohort design when the cohort design had a better confounder control strategy. We discussed the strengths and drawbacks of case-time-control design.

KW - antidepressants

KW - case-time-control

KW - cohort design congenital heart defects

KW - pharmacoepidemiology

KW - pregnancy

U2 - 10.1002/pds.4844

DO - 10.1002/pds.4844

M3 - Journal article

C2 - 31359557

VL - 28

SP - 1180

EP - 1193

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 9

ER -